MktsMarkets

Vera Therapeutics, Inc.
NASDAQ: VERAKey statistics
VERA News
Stories mentioning VERA from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 86,011 | 59,310 | 56,473 | 58,195 | 41,278 | 33,347 | 40,314 | 29,311 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 125,132 | 94,206 | 83,932 | 80,141 | 57,194 | 48,914 | 49,801 | 37,343 |
| Operating Income (Loss) | (125,132) | (94,206) | (83,932) | (80,141) | (57,194) | (48,914) | (49,801) | (37,343) |
| Interest Income | 6,355 | 5,517 | 5,736 | 6,320 | 6,906 | 6,663 | 4,761 | 5,104 |
| Interest Expense | 1,912 | |||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (121,032) | (91,097) | (80,293) | (76,531) | (51,694) | (43,425) | (46,632) | (33,708) |
| Earnings Per Share (Basic) | (1.69) | (1.42) | (1.26) | (1.20) | (0.81) | (0.78) | (0.85) | (0.62) |
| Earnings Per Share (Diluted) | (1.69) | (1.42) | (1.26) | (1.20) | (0.81) | (0.78) | (0.85) | (0.62) |
| Weighted Average Shares Outstanding (Basic) | 71,477 | 64,234 | 63,847 | 63,789 | 63,672 | 55,327 | 54,898 | 54,729 |
| Weighted Average Shares Outstanding (Diluted) | 71,477 | 64,234 | 63,847 | 63,789 | 63,672 | 55,327 | 54,898 | 54,729 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About VERA
Vera Therapeutics, Inc. (NASDAQ: VERA) is a stock listed on the Nasdaq Stock Market under the ticker symbol VERA. It last traded at $30.53 (Oct 29, 2026, 9:30 AM ET), down 1.3% on the day. That gives Vera Therapeutics a market capitalisation of $2.2B.
Over the past 52 weeks VERA has traded between $23.05 and $56.05.
For the quarter ended Mar 31, 2026 it reported a net loss of $121.0M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$121.0M |
| Dec 31, 2025 | — | -$91.1M |
| Sep 30, 2025 | — | -$80.3M |
| Jun 30, 2025 | — | -$76.5M |
From Vera Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…